Long-term trastuzumab biotherapy of a breast cancer patient
L. N Volodina , E. P Kulikov , A. V Grigoryev , M. P Bublokova , O. P Zhuravleva , V. V Chernova , R. E Kolobaeva , E. L Sashina , L. A Sonina , Sergey A. Mertsalov , A. S Mirchetich , I. Yu Vinogradov , M. Yu Kholchev
Russian Journal of Oncology ›› 2015, Vol. 20 ›› Issue (5) : 31 -33.
Long-term trastuzumab biotherapy of a breast cancer patient
The paper describes a clinical case of long-term Trastuzumab biotherapy of a patient with HER2-positive breast cancer. The patient with morphology confirmed HER2+ breast cancer has received Trastuzumab therapy over 9 years. CT data proved complete resorption of metastases in the lungs. No adverse events, which could limit trastuzumab treatment, were noted. The clinical case illustrates effective long-term Trastuzumab therapy of a patient with metastatic HER2+ breast cancer.
long-term Trastuzumab therapy / metastatic breast cancer
| [1] |
Семиглазов В.Ф., Семиглазов В.В., Палтуев Р.М. Биологическое обоснование планирования лечения рака молочной железы. Врач. 2012; 11: 2-4. |
| [2] |
Белохвостова А.С., Смирнова И.А., Енилеева А.А. Таргетная терапия в лечении HER2-позитивного рака молочной железы. Сибирский онкологический журнал. 2013; 2 (56): 84-8. |
| [3] |
Minckwitz G. Trastuzumab beyond progression in epidermal growth factor receptor 2-positive advanced breast cancer a German breast croup 26/ breast international group 03-05 study. J. Clin. Oncol. 2009; 27: 1999-2006. |
| [4] |
Rueckert S., Ruehl I., Kahlert S. et al. A monoclonal antibody as an effective therapeutic agent in breast cancer. Trastuzumab. Biol. Ther. 2005; 5 (6): 853-66. |
| [5] |
Фролова М.А. Наиболее значимые итоги 2012 года в лечении рака молочной железы. Практическая онкология. 2013; 14 (1): 51-8. |
| [6] |
Baselga J., Cortes J., Kim S.B. et al. Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012; 366 (2): 109-19. |
Eco-Vector
/
| 〈 |
|
〉 |
PDF
